Character Biosciences has secured $93 million in Series B funding to support two lead programmes aimed at treating age-related macular degeneration, a major cause of vision loss for people over 60. The firm uses artificial intelligence to maximise clinical trial data’s value and will start phase 1 testing for both programmes later this year.
Gen Z’s Rising Susceptibility to Social Engineering Attacks
Recent studies suggest Generation Z is more susceptible to social engineering attacks than older generations due to complacency, impulsivity, overconfidence, and a lack of cybersecurity
